Le Lézard
Classified in: Health, Science and technology
Subject: ANNUAL MEETINGS

DiaMedica Therapeutics Announces Results of Annual General and Special Meeting of Shareholders


MINNEAPOLIS, Dec. 21, 2017 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (TSX-V:DMA) (OTCQB:DMCAF) (the "Company"), today announced that at its Annual General and Special Meeting (the "Meeting") of shareholders held on December 21, 2017, the shareholders approved all the resolutions placed before the Meeting and as outlined in the Management Information Circular dated November 17, 2017. Dr. Michael Giuffre, James Parsons, Rick Pauls, Richard Pilnik, and Dr. Jerry Xiao were reelected as the Company's board of directors. 

About DiaMedica Therapeutics Inc.

DiaMedica Therapeutics is a clinical stage biopharmaceutical company focused on developing novel treatments for neurological and kidney diseases. DiaMedica's shares are listed on the TSX Venture Exchange under the trading symbol "DMA" and on the OTCQB under the trading symbol "DMCAF". For more information, please visit www.diamedica.com. Follow us on social media ? Twitter, LinkedIn.

For further information, please contact:
Paul Papi
Vice President of Business Development
DiaMedica Therapeutics Inc.
Two Carlson Parkway, Suite 260
Minneapolis, MN
Phone: (617) 899-5941
[email protected]

Tweet this!

FORWARD-LOOKING STATEMENTS

The statements made in this press release that are not historical facts contain forward-looking information that involves risk and uncertainties. All statements, other than statements of historical facts, which address DiaMedica's expectations, should be considered forward-looking statements. Such statements are based on management's exercise of business judgment as well as assumptions made by and information currently available to management. When used in this document, the words "may", "will", "anticipate", "believe", "estimate", "expect", "intend" and words of similar import, are intended to identify any forward-looking statements. You should not place undue reliance on these forward-looking statements. These statements reflect a current view of future events and are subject to certain risks and uncertainties as contained in the DiaMedica's filings with the Canadian securities regulators, all of which are available on SEDAR (www.sedar.com). Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results could differ materially from those anticipated in these forward-looking statements. DiaMedica undertakes no obligation, and does not intend to update, revise or otherwise publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof, or to reflect the occurrence of any unanticipated events, unless required by law. Although management believes that expectations are based on reasonable assumptions, no assurance can be given that these expectations will materialize.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of the contents of this press release.


These press releases may also interest you

at 11:45
SummaryProduct: Henna cones Issue: Chemical hazard / Product safety What to do: Stop using and selling them immediately and dispose of them in regular household garbage Who this is for: General public / Industry; Retail, Importers IssueHealth Canada...

at 11:30
The "Global Antibody Therapeutic Market: Focus on Format, Disease Area, Route of Administration, End Users, Region, and Competitive Landscape - Analysis and Forecast, 2024-2033" report has been added to  ResearchAndMarkets.com's offering. The global...

at 11:30
XtalPi Inc., a leading global technology company in integrating artificial intelligence (AI) and robotics to advance the discovery of groundbreaking medicine and innovative materials, announced today the launch of its proprietary comprehensive solid...

at 11:25
Manifest Technologies, Inc., developer of an AI-powered computational neuro-imaging platform for CNS disease, today unveiled the company after completing its initial funding and partnership with a top five global pharmaceutical company. Today, over...

at 11:08
Sunwave Health, a leader in healthcare technology, proudly announces the launch of MARA, a patent-pending, innovative AI Agent designed to transform the landscape of behavioral health documentation. Since its launch on October 25, 2023, MARA has...

at 11:04
MelliCell Inc. has been awarded a U.S. National Science Foundation (NSF) Small Business Innovation Research (SBIR) grant for $275,000 to conduct research and development (R&D) work on "Industrial Scale Technology for Drug Development in Mature Human...



News published on and distributed by: